Pateclizumab Biosimilar, Anti-human LT alpha (LT-α) Monoclonal Antibody | C060P

Catalog No.	C060P
Product Name	Pateclizumab Biosimilar, Anti-human LT alpha (LT-α) Monoclonal Antibody | C060P
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Source/Host	The anti-human lymphotoxin alpha (LT-α) monoclonal antibody pateclizumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade pateclizumab biosimilar specifically binds to the human lymphotoxin alpha (LT-α).
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by pateclizumab.
Form Of Antibody	0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 0.1 EU per 1 ug of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The research grade pateclizumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5019 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card.

Description

C060P: Pateclizumab Biosimilar (Research Grade), Anti-human Lymphotoxin Alpha (LT-α) Monoclonal Antibody

Recombinant Humanized IgG1 kappa Monoclonal Antibody.

Background

Pateclizumab Biosimilar uses the same protein sequences as the therapeutic antibody pateclizumab.

Pateclizumab is an immunoglobulin G1 kappa (IgG1κ) monoclonal antibody targeting lymphotoxin alpha (LT-α) for the treatment of rheumatoid arthritis. A phase I study has assessed the safety, pharmacokinetics, and biologic activity of pateclizumab, and found that pateclizumab was generally well-tolerated in RA patients. Pateclizumab also has been investigated in clinical trial to study its efficacy and safety in combination with a disease-modifying anti-rheumatic drug (DMARD) compared with adalimumab in combination with a DMARD in patients with active rheumatoid arthritis.

LT-α is a member of tumor necrosis factor superfamily family (TNFSF) and products by predominately by activated cells of the innate and adaptive immune response. Lymphotoxin α formerly named tumor necrosis factor-beta (TNF-β) as it is a homologous protein to TNFα. When LTβ is discovered, TNF-β was renamed LT-α. LT-α plays different roles in immune regulation as its different secreted forms. LTα binds to TNF receptor 1 (TNFR1) and TNFR2 to promote inflammation as a form of soluble homotrimeric molecule (LTα3); whereas cell-bound LTα1β2 (LT-α complex with LTβ as LTα1β2 heterotrimers on the surface of activated B, Th1 and Th17 cells) bind LTβ receptors (LTβR) to mediate signaling pathway.

Rheumatoid arthritis (RA) is an autoimmune disorder associated with progressive joint damage, pain, fatigue, and disability. TNF α is reported to be the main factor promoting the development of RA, so targeting TNFα is regarded as the routine method of RA treatment. However, a large number of RA patients did not respond to TNFα therapy, which prompted us to seek new treatments. In addition to TNFα, other cytokines have also been reported to be involved in the pathogenesis of RA, and LT- α is one of them. It was found that two forms of LTα homotrimer (LTα3 and LTα1β2) increased in synovial fluid of RA patients, while the LTα, LTβ and LTβR transcripts increased in synovium respectively. Study has demonstrated that the depletion of CD4 T helper (Th) subsets Th1 and Th17 (with high levels of surface LTα1β2) by mouse LTα specific monoclonal antibody showed therapeutic efficacy in the preclinical mouse model of RA, which suggests the treatment possibility targeting LTα. Thus, humanized pateclizumab was designed to target LTα, binding to both the soluble LTα3 homotrimeric form and the surface-expressed LTα1β2 heterotrimer, for the treatement of RA. By blocking the binding of LTα3 and LTα1β2 to its cognate receptors LTβR and TNFR, pateclizumab specificly deplete of activated cells and inhibit the immune cell trafficking and/or recruitment to inflammatory sites. Depletion is limited to cells that express LTα1β2 on the surface, which improves the targeting of therapy.

Syd Labs provides a number of research grade antibody biosimilar proteins with competitive prices starting from $3/mg. Syd Labs also introduces mutations to the antibody biosimilars including engineering or switching the isotypes or Fc engineering, such as Fc silent.

Syd Labs also produces the in vivo grade isotype control antibodies. Some customers purchase them for in vitro assays such as flow cytometry or immunohistochemistry (IHC) because the prices are too good if compared to those research reagents of antibody isotype controls . Syd Labs provides the following in vivo grade recombinant human IgG1 kappa isotype control antibody proteins and mutants:

In vivo grade recombinant human IgG1 isotype control antibody
In vivo grade recombinant human IgG1 Fc protein
In vivo grade recombinant human IgG1-D265A isotype control antibody
In vivo grade recombinant human IgG1-N297A isotype control antibody
In vivo grade recombinant human IgG1-D265A N297A isotype control antibody
In vivo grade recombinant human IgG1-L234A L235A P329G (LALAPG) isotype control antibody

Frequent questions related to “research grade pateclizumab biosimilar, anti-human lymphotoxin alpha (LT-α) monoclonal antibody”:

Does pateclizumab bind mouse LT-α?
Is pateclizumab humanized?
What is the mechanism of action for pateclizumab?

Popular searches related to “research grade pateclizumab biosimilar, anti-human lymphotoxin alpha (LT-α) monoclonal antibody”:

pateclizumab monoclonal antibody
pateclizumab purchase
pateclizumab mechanism of action
pateclizumab price
LT-α mouse cell line
Pateclizumab Biosimilar Research Grade
Lymphotoxin alpha
Lymphotoxin
LT-α

No more offers for this product!